Satoshi Hamauchi

1.1k total citations
71 papers, 697 citations indexed

About

Satoshi Hamauchi is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Otorhinolaryngology. According to data from OpenAlex, Satoshi Hamauchi has authored 71 papers receiving a total of 697 indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Pulmonary and Respiratory Medicine, 30 papers in Surgery and 28 papers in Otorhinolaryngology. Recurrent topics in Satoshi Hamauchi's work include Head and Neck Cancer Studies (28 papers), Gastric Cancer Management and Outcomes (20 papers) and Oral health in cancer treatment (14 papers). Satoshi Hamauchi is often cited by papers focused on Head and Neck Cancer Studies (28 papers), Gastric Cancer Management and Outcomes (20 papers) and Oral health in cancer treatment (14 papers). Satoshi Hamauchi collaborates with scholars based in Japan, United States and Italy. Satoshi Hamauchi's co-authors include Tomoya Yokota, Yusuke Onozawa, Hirofumi Yasui, Akiko Todaka, Hirofumi Ogawa, Tetsuro Onitsuka, Takahiro Tsushima, Kentaro Yamazaki, Akira Fukutomi and Nozomu Machida and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Satoshi Hamauchi

60 papers receiving 688 citations

Peers

Countries citing papers authored by Satoshi Hamauchi

Since Specialization

Citations

This map shows the geographic impact of Satoshi Hamauchi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Satoshi Hamauchi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Satoshi Hamauchi more than expected).

Fields of papers citing papers by Satoshi Hamauchi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Satoshi Hamauchi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Satoshi Hamauchi. The network helps show where Satoshi Hamauchi may publish in the future.

Co-authorship network of co-authors of Satoshi Hamauchi

This figure shows the co-authorship network connecting the top 25 collaborators of Satoshi Hamauchi. A scholar is included among the top collaborators of Satoshi Hamauchi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Satoshi Hamauchi. Satoshi Hamauchi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	Phase 1/2 study of liposomal irinotecan plus S-1 for metastatic pancreatic cancer refractory to gemcitabine-based treatment	European Journal of Cancer	Hiroshi Imaoka, Masafumi Ikeda et al.	0
2	Phase II trial of enfortumab vedotin in patients with previously treated gastric and esophageal cancers	ESMO Open	Steven B. Maron, Keisho Chìn et al.	0
3	Enfortumab vedotin (EV) in previously treated gastric/esophageal cancers cohorts of EV-202.	Journal of Clinical Oncology	Kei Muro, Keisho Chìn et al.	2
4	Lenvatinib rechallenge after failure of lenvatinib and sorafenib in metastatic thyroid cancer	Investigational New Drugs	Tomoya Yokota, Satoshi Hamauchi et al.	0
5	Genetic medicine in companion diagnostics of germline BRCA testing of Japanese pancreatic cancer patients	Journal of Human Genetics	Hiroyuki Matsubayashi, Akiko Todaka et al.	7
6	Effectiveness and safety of gemcitabine plus nab-paclitaxel in elderly patients with advanced pancreatic cancer: a single-center retrospective cohort study	Investigational New Drugs	Akiko Todaka, Hiroshi Nakase et al.	3
7	Prognostic impact of the number of metastatic lymph nodes after surgery in locally advanced hypopharyngeal cancer	BMC Cancer	Tomoya Yokota, Satoshi Hamauchi et al.	6
8	Phase 3 Randomized Trial of Topical Steroid Versus Placebo for Prevention of Radiation Dermatitis in Patients With Head and Neck Cancer Receiving Chemoradiation	International Journal of Radiation OncologyBiologyPhysics	Tomoya Yokota, Sadamoto Zenda et al.	19
9	Chemoradiotherapy for high-risk stage II laryngeal cancer	International Journal of Clinical Oncology	Satoshi Hamauchi, Tomoya Yokota et al.	4
10	Efficacy and feasibility of induction chemotherapy with paclitaxel, carboplatin and cetuximab for locally advanced unresectable head and neck cancer patients ineligible for combination treatment with docetaxel, cisplatin, and 5-fluorouracil	International Journal of Clinical Oncology	Hiromichi Shirasu, Tomoya Yokota et al.	12
11	Risk factors for esophageal fistula in thoracic esophageal squamous cell carcinoma invading adjacent organs treated with definitive chemoradiotherapy: a monocentric case-control study	BMC Cancer	Takeshi Kawakami, Takahiro Tsushima et al.	40
12	The phase II study of HMB/Arg/Gln against oral mucositis induced by chemoradiotherapy for head and neck cancer patients	Annals of Oncology	Tomoya Yokota, Satoshi Hamauchi et al.	1
13	Role of hepatectomy in gastric cancer with multiple liver-limited metastases	Gastric Cancer	Hiromichi Shirasu, Takahiro Tsushima et al.	31
14	Risk factors for aspiration pneumonia after definitive chemoradiotherapy or bio-radiotherapy for locally advanced head and neck cancer: a monocentric case control study	BMC Cancer	S. Kawai, Tomoya Yokota et al.	26
15	Efficacy and safety of irinotecan monotherapy as third-line treatment for advanced gastric cancer	Cancer Chemotherapy and Pharmacology	Takeshi Kawakami, Nozomu Machida et al.	28
16	Multicenter phase II study of an oral care program for patients with head and neck cancer receiving chemoradiotherapy	Supportive Care in Cancer	Tomoya Yokota, Hiroyuki Tachibana et al.	33
17	169P Serum CA19-9 response is an early predictive marker for the efficacy of regorafenib in refractory metastatic colorectal cancer	Annals of Oncology	Hiroya Taniguchi, Yosuke Kito et al.	0
18	Excessive watering eyes in gastric cancer patients receiving S-1 chemotherapy	Gastric Cancer	Satoshi Hamauchi, Takahiro Tsushima et al.	5
19	Distinctive mucositis and feeding-tube dependency in cetuximab plus radiotherapy for head and neck cancer	Japanese Journal of Clinical Oncology	Tomoya Yokota, Satoshi Hamauchi et al.	16
20	Efficacy and feasibility of docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy for locally advanced head and neck squamous cell carcinoma classified as clinical nodal stage N2c, N3, or N2b with supraclavicular lymph node metastases	International Journal of Clinical Oncology	Naoki Izawa, Yusuke Onozawa et al.	19

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact